-DOCSTART- -X- O
Viral -X- _ O
diseases -X- _ O
remain -X- _ O
serious -X- _ O
threats -X- _ O
to -X- _ O
public -X- _ O
health -X- _ O
because -X- _ O
of -X- _ O
the -X- _ O
shortage -X- _ O
of -X- _ O
effective -X- _ O
means -X- _ O
of -X- _ O
control. -X- _ O
To -X- _ O
combat -X- _ O
the -X- _ O
surge -X- _ O
of -X- _ O
viral -X- _ O
diseases -X- _ O
, -X- _ O
new -X- _ O
treatments -X- _ O
are -X- _ O
urgently -X- _ O
needed. -X- _ O
Here -X- _ O
we -X- _ O
show -X- _ O
that -X- _ O
small-molecules -X- _ B-Intervention
, -X- _ O
which -X- _ O
inhibit -X- _ B-Intervention
cellular -X- _ B-Patient
anti-apoptotic -X- _ I-Patient
Bcl-2 -X- _ I-Patient
proteins -X- _ I-Patient
( -X- _ I-Patient
Bcl-2i -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
induced -X- _ B-Outcome
the -X- _ I-Outcome
premature -X- _ I-Outcome
death -X- _ I-Outcome
of -X- _ I-Outcome
cells -X- _ I-Outcome
infected -X- _ I-Outcome
with -X- _ I-Outcome
different -X- _ I-Outcome
RNA -X- _ I-Outcome
or -X- _ I-Outcome
DNA -X- _ I-Outcome
viruses -X- _ I-Outcome
, -X- _ O
whereas -X- _ O
, -X- _ O
at -X- _ O
the -X- _ O
same -X- _ O
concentrations -X- _ O
, -X- _ O
no -X- _ B-Outcome
toxicity -X- _ I-Outcome
was -X- _ I-Outcome
observed -X- _ I-Outcome
in -X- _ I-Outcome
mock-infected -X- _ I-Outcome
cells. -X- _ I-Outcome
Moreover -X- _ O
, -X- _ O
these -X- _ B-Outcome
compounds -X- _ I-Outcome
limited -X- _ I-Outcome
viral -X- _ I-Outcome
replication -X- _ I-Outcome
and -X- _ I-Outcome
spread. -X- _ I-Outcome
Surprisingly -X- _ O
, -X- _ O
Bcl-2i -X- _ B-Outcome
also -X- _ I-Outcome
induced -X- _ I-Outcome
the -X- _ I-Outcome
premature -X- _ I-Outcome
apoptosis -X- _ I-Outcome
of -X- _ I-Outcome
cells -X- _ I-Outcome
transfected -X- _ I-Outcome
with -X- _ I-Outcome
viral -X- _ I-Outcome
RNA -X- _ I-Outcome
or -X- _ I-Outcome
plasmid -X- _ I-Outcome
DNA -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
of -X- _ I-Outcome
mock-transfected -X- _ I-Outcome
cells. -X- _ I-Outcome
These -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
Bcl-2i -X- _ B-Outcome
sensitizes -X- _ I-Outcome
cells -X- _ I-Outcome
containing -X- _ I-Outcome
foreign -X- _ I-Outcome
RNA -X- _ I-Outcome
or -X- _ I-Outcome
DNA -X- _ I-Outcome
to -X- _ I-Outcome
apoptosis. -X- _ I-Outcome
A -X- _ O
comparison -X- _ O
of -X- _ O
the -X- _ O
toxicity -X- _ O
, -X- _ O
antiviral -X- _ O
activity -X- _ O
, -X- _ O
and -X- _ O
side -X- _ O
effects -X- _ O
of -X- _ O
six -X- _ O
Bcl-2i -X- _ O
allowed -X- _ O
us -X- _ O
to -X- _ O
select -X- _ O
A-1155463 -X- _ O
as -X- _ O
an -X- _ O
antiviral -X- _ O
lead -X- _ O
candidate. -X- _ O
Thus -X- _ O
, -X- _ O
our -X- _ O
results -X- _ O
pave -X- _ O
the -X- _ O
way -X- _ O
for -X- _ O
the -X- _ O
further -X- _ O
development -X- _ O
of -X- _ O
Bcl-2i -X- _ O
for -X- _ O
the -X- _ O
prevention -X- _ O
and -X- _ O
treatment -X- _ O
of -X- _ O
viral -X- _ O
diseases -X- _ O
. -X- _ O

